Faeth Therapeutics (FTH) highlighted its PIKTOR program—a dual-oral inhibitor targeting the PI3K/AKT/mTOR pathway—as a potential breakthrough in endometrial and breast cancer treatment at the September 10, 2026, Cantor Fitzgerald Global Healthcare Conference. The company’s Phase I-B study demonstrated a 47% overall response rate, including complete responses, with tolerability profiles distinct from intravenous alternatives like Gedatolisib. PIKTOR’s oral formulation delivers sustained exposure at 2- to 3-times the inhibitory concentration (IC90), unlike competitors that peak at 50-times IC90 before falling below efficacy thresholds within 14–15 hours of administration. This pharmacokinetic advantage may reduce side effects such as stomatitis, according to the company’s data from skin punch biopsies showing pathway shutdown at Phase II doses of 200 mg (serabelisib) and 3 mg (sapanisertib).
The presentation underscored PIKTOR’s multi-node inhibition strategy, addressing resistance mechanisms observed in single-target therapies. Lewis Cantley, co-founder of Faeth and discoverer of the PI3K pathway, emphasized that dual inhibition of PI3K-alpha and TORC1/2 prevents reactivation of downstream signaling, a common challenge in cancer treatment. The company’s Phase II data for endometrial cancer are expected by year-end 2024, with full breast cancer dataset results anticipated by year-end 2027. Phase III trials may begin as early as 2028, pending regulatory approvals.
Faeth raised $200 million in a PIPE transaction in 2024, bolstering its cash position to over $186 million as of Q2 2026. The company’s lead program, PIKTOR, targets endometrial and breast cancers—both frequently associated with obesity and metabolic disorders, with 90% of endometrial cancer patients classified as pre-diabetic or diabetic. Comparisons to competitors like Sacituzumab govitecan (30%–35% response rate, 6–7 months progression-free survival) and Inavolisib (16% monotherapy response rate in PI3KCA-mutant populations) underscore PIKTOR’s potential efficacy in refractory settings. Faeth’s oral advantage, combined with its multi-pathway approach, positions PIKTOR as a candidate to compete with established intravenous therapies in both indications.
The company’s presentation also referenced prior work by Takeda in HR-positive, HER2-negative breast cancer, where 5-year mortality stands at ~50%. In endometrial cancer, the 5-year mortality rate is ~85%, highlighting unmet need in both indications. Faeth’s focus on multi-node inhibition aligns with broader trends in precision oncology, where resistance mechanisms remain a hurdle for single-target therapies. The company’s approach, combining efficacy, tolerability, and oral delivery, could redefine treatment paradigms for PI3K-driven cancers.
